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Abstract
Background: CD44 is a polymorphic proteoglycan and functions as the principal cell-surface receptor for hyaluronate (HA).
Heparin-binding epidermal growth factor (HB-EGF) activation of keratinocyte erbB receptors has been proposed to mediate
retinoid-induced epidermal hyperplasia. We have recently shown that intermediate size HA fragments (HAFi) reverse skin
atrophy by a CD44-dependent mechanism.
Methodology and Principal Findings: Treatment of primary mouse keratinocyte cultures with retinaldehyde (RAL) resulted
in the most significant increase in keratinocyte proliferation when compared with other retinoids, retinoic acid, retinol or
retinoyl palmitate. RAL and HAFi showed a more significant increase in keratinocyte proliferation than RAL or HAFi alone. No
proliferation with RAL was observed in CD44
2/2 keratinocytes. HA synthesis inhibitor, 4-methylumbelliferone inhibited the
proliferative effect of RAL. HB-EGF, erbB1, and tissue inhibitor of MMP-3 blocking antibodies abrogated the RAL- or RAL- and
HAFi-induced keratinocyte proliferation. Topical application of RAL or RAL and HAFi for 3 days caused a significant
epidermal hyperplasia in the back skin of wild-type mice but not in CD44
2/2 mice. Topical RAL and HAFi increased
epidermal CD44 expression, and the epidermal and dermal HA. RAL induced the expression of active HB-EGF and erbB1.
However, treatment with RAL and HAFi showed a more significant increase in pro-HB-EGF when compared to RAL or HAFi
treatments alone. We then topically applied RAL and HAFi twice a day to the forearm skin of elderly dermatoporosis
patients. After 1 month of treatment, we observed a significant clinical improvement.
Conclusions and Significance: Our results indicate that (i) RAL-induced in vitro and in vivo keratinocyte proliferation is a
CD44-dependent phenomenon and requires the presence of HA, HB-EGF, erbB1 and MMPs, (ii) RAL and HAFi show a
synergy in vitro and in vivo in mouse skin, and (iii) the combination of RAL and HAFi seems to have an important therapeutic
effect in dermatoporosis.
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Introduction
CD44 is a facultative cell surface proteoglycan expressed as
several isoforms [1,2] and the principal cell surface receptor of
hyaluronate [3,4] (HA), the major component of the extracellular
matrix [5]. In our previous study we have shown that CD44 is
implicated in the regulation of keratinocyte proliferation and the
local HA metabolism in mice [6].
We have recently shown that the epidermal hyperplasia induced
by topical retinoids was accompanied by an increased expression
of CD44 and hyaluronate synthases and associated with an
increase in epidermal and dermal HA in mouse skin [7]. We have
also shown that the decrease of the expression of CD44 and
hyaluronate induced by UVA and UVB in mouse epidermis is
counteracted by topical retinoids [8]. Topical application of one of
these retinoids, retinaldehyde (RAL), a natural retinoid immediate
precursor of retinoic acid (RA), restores the epidermal thickness
and CD44 expression which are correlated with clinical
improvement in lichen sclerosus et atrophicus (LSA) lesions [9],
where the epidermal expression of CD44 has been shown to be
decreased or absent [10].
RAL has been shown to exert biological activity in mouse and
human skin [11,12]. It has been shown that the epidermal
hyperplasia induced by topical retinoids was linked to a RA
receptor (RAR)-dependent heparin-binding epidermal growth
factor (HB-EGF) paracrine loop [13]. It has also been shown that
a heparan sulfate-bearing variant of CD44 (CD44v3) recruits
proteolytically active matrix metalloproteinase 7 (MMP-7), the
precursor of HB-EGF (pro-HB-EGF) and its receptor, erbB4 to
form a complex on the cell surface [14]. We have recently shown
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14372that CD44 is colocalized with another HB-EGF receptor, erbB1
on keratinocytes [15]. We have also shown that topically applied
HAF of intermediate size (HAFi) traverse the skin and induce a
CD44-dependent biological effect characterized by a skin
regeneration in mice and elderly human patients showing
dermatoporosis, the holistic word for human skin fragility and
an emerging clinical problem due to chronological aging, long-
term sun exposure and chronic use of corticosteroids [15,16,17].
To see whether retinoid-induced epidermal hyperplasia via HB-
EGF was a CD44-related phenomenon, we compared the effect of
different retinoids on in vitro proliferation of keratinocytes DBA/1
mice. We further tested the effect of the blockade of HA synthesis,
HB-EGF, erbB1 and MMPs including MMP-7 on the proliferation
of the keratinocytes of SKH1 hairless, DBA/1 and CD44-deficient
(CD44
2/2) mice. We also analyzed the effect of RAL
on the epidermal hyperplasia in SKH1 hairless, DBA/1 and
CD44
2/2 mice, and in vivo expression of CD44v3, MMP-7, HB-
EGF and its receptors in SKH1 hairless mice. To address the
possibility that RAL and HAFi may have a synergy on keratinocyte
proliferation and epidermal hyperplasia, we examined the effect of
the combination of HAFi and RAL on the mouse skin in vitro and in
vivo, and on atrophic skin of elderly patients with dermatoporosis.
Results
RAL is the most potent retinoid to induce keratinocyte
proliferation
To determine the effect of different retinoids on in vitro
keratinocyte proliferation, we established primary cultures of
keratinocytes from DBA/1 mice. Treatment of mouse keratino-
cytes with 2 mM of RAL resulted in slight but the most significant
increase in keratinocyte proliferation when compared to retinoic
acid (RA), retinol (ROL) or retinoyl palmitate (ROLP) (Figure 1A).
RAL-induced HA synthesis is required for keratinocyte
proliferation
To explore the role of HA synthesized by keratinocytes on
RAL-induced keratinocyte proliferation, the keratinocytes of
DBA/1 mice were treated with an HA synthesis inhibitor, 4-
methylumbelliferone (4-MU), or hyaluronidase. RAL-induced
keratinocyte proliferation was inhibited by 4-MU added to the
cultures before or in the mean time with RAL (Figure 1B).
In vitro proliferation of CD44-deficient keratinocytes is
defective in response to RAL
To further address the importance of the presence of CD44 in
this proliferative effect, we tested the ability of proliferation of
keratinocytes of CD44-deficient (CD44
2/) mice in response to
RAL. In contrast to normal keratinocytes, no proliferation was
observed in CD44
2/2 cells (Figure 1C).
Anti-HB-EGF, anti-erbB1 and TIMP-3 inhibits RAL-induced
keratinocyte proliferation in vitro
Since HB-EGF is thought to be involved in retinoid-induced
epidermal hyperplasia and because keratinocytes normally express
several CD44 isoforms, including exon v3-containing variants
(CD44v3) [18], which are substituted in heparan sulfate side chains
and form a complex with matrix metalloproteinase 7 (MMP-7),
heparin binding epidermal growth factor (HB-EGF) precursor (pro-
HB-EGF) and its receptors (erbB4, erbB1) [14,15], we first
compared the ability of CD44
2/2 and normal keratinocytes to
proliferate in response to HB-EGF. HB-EGF (50 ng/ml) stimulated
the proliferation of wild-type DBA/1 and, to a lesser extent, SKH1
hairless keratinocytes, whereas only a slight proliferation increase
was observed in CD44-deficient keratinocytes (Figure 1C). We
further analyzed the requirement of HB-EGF and its receptors in
RAL-induced keratinocyte proliferation. Since erbB4 is not
expressed in neither mouse [19] nor human [20] keratinocytes
and erbB1 (epidermal growth factor receptor [EGFR]) is the
principal receptor of HB-EGF in human keratinocytes [15,20], we
testedthe cultured keratinocytes of SKH1 hairless and DBA/1 mice
for response to RAL in the presence of anti-HB-EGF (100 ng/ml)
or anti-erbB1 (100 ng/ml) neutralizing antibodies. Anti-HB-EGF
significantly inhibited RAL-induced proliferative response in
normal keratinocytes (Figure 1C). Blocking antibodies against
amphiregulin (AR), a growth factor which fails to bind CD44v3
[21], did not inhibit keratinocyte proliferation (Figure 1D). In
contrast, anti-erbB1 significantly blocked the proliferation of
keratinocytes (Figure 1D). Since MMP-7 was shown to form a
complex with its substratepro-HB-EGF and CD44v3 on the surface
of some cells and MMPs [14] and the related a disintegrin and
metalloproteinase (ADAM) family proteases [22] activate HB-EGF,
we also tested the effect of tissue inhibitor of metalloproteinase-3
(TIMP-3) which inhibits the effect of MMPs including MMP-7 and
of ADAMs, on the keratinocyte proliferation induced by RAL.
Incubation of the keratinocytes of SKH1 hairless and DBA/1 mice
withTIMP-3(100 ng/ml)abrogatedtheRAL-inducedkeratinocyte
proliferation (Figure 1D).
RAL and HAFi show a synergy in in vitro proliferative
response of mouse keratinocytes which is CD44- and HB-
EGF-dependent
To address the effect of the combination of different retinoids and
HAFi on keratinocyte proliferation, we tested the response to
100 mg/ml of HAFi and 2 mM of ROL, RAL, RA and ROLP of
cultured keratinocytes from the back skin of DBA/1 mice. Exposure
to HAFi and RAL resulted in a more significant increase in
keratinocyte proliferation than HAFi with other retinoids
(Figure 1A). HAFi and RAL combination was more efficient in
the proliferation of keratinocytes from the back skin of SKH1
hairless and DBA/1 mice than RAL or HAFi alone, whereas no
proliferation was observed in CD44
2/2 cells (Figure 1D). The
proliferative response was slightly higher in DBA/1 keratinocytes
(Figure 1C). Additionof blockinganti-HB-EGF antibodies (100 ng/
ml) to RAL- and HAFi-treated cultures abrogated the proliferative
response as in only RAL- or HAFi-treated cultures (Figure 1D).
The effect of RAL and HAFi in vivo is CD44-dependent
Topical application of the combination of 0.05% RAL and
0.2% HAFi for 3 days resulted in a significant epidermal
hyperplasia in the follicular (data not shown) and interfollicular
epidermis in SKH1 hairless and DBA/1 mice (Figure 2A). This
hyperplasia was more significant when compared to that induced
by RAL alone, but it was comparable to that induced by HAFi
alone (Figure 2B). In addition, topically applied RAL and HAFi
significantly increased the number of Ki-67-positive cells in the
epidermis and dermis (Figure 2C). The increase in epidermal Ki-
67-positive cells was comparable to that with RAL or HAFi alone
(data not shown). However, the increase in dermal Ki-67-positive
cells was superior to that with RAL alone but it was not different
when compared with the one with HAFi alone (data not shown).
In contrast, topical application of RAL and HAFi, alone or in
combination, to the back skin of CD44
2/2 mice did not result in
epidermal hyperplasia or keratinocyte proliferation (Figure 2A, B,
C, data not shown). Topically applied RAL and HAFi, as HAFi
alone but not RAL alone, led to an increased cellularity in the
HA-RAL Synergy in Skin
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not in CD44
2/2 mice (data not shown).
In vivo proliferative response of mouse epidermis to RAL
is CD44-dependent
The effect of skin CD44 expression loss on epidermal hyperplasia
induced by topically-applied RAL was addressed by comparing the
histology of retinoid-treated skin areas of CD44
2/2 and normal
littermates. Topical application of 0.05% RAL for 3 days resulted in
a significant epidermal hyperplasia and keratinocyte proliferation as
determined by quantitation of Ki67 in the back skin of SKH1
hairless and DBA/1 mice, whereas no epidermal hyperplasia and
keratinocyte proliferation was observed in CD44
2/2 mice.
(Figure 2A, B, C).
Figure 1. The effect of retinoids and HAFi in vitro.A .RAL is the most potent retinoid to induce keratinocyte proliferation. Keratinocytes from
DBA/1 mice were cultured in 96-well plates. On day 2 of culture, HAFi (100 mg/ml), RAL (2 mM), RA (2 mM), ROL (2 mM), ROLP (2 mM), RAL+HAFi,
RA+HAFi, ROL+HAFi or ROLP+HAFi was added to the cultures. 48 hrs later 1 mCi of [
3H]thymidine was added to each well. All experiments were done
in triplicate and repeated 5 times. The results are presented as the mean incorporated counts per minute 6 SEM of three wells per group.
***p,0.001(HAFi versus none; RAL versus none, RA, ROL and ROLP; RAL+HAFi versus all; ROL+HAFi versus none; RA+HAFi versus none; ROLP+HAFi
versus none) (student’s t test). B. RAL-induced HA synthesis is required for keratinocyte proliferation. Keratinocytes from DBA/1 mice were cultured in
96-well plates. On day 2 of culture, RAL (2 mM), 4-MU (0.6 mM) [alone or together with RAL (RAL+4-MU) or 30 (4-MU-30+RAL) or 60 (4-MU-60+RAL)
minutes before RAL] or hyaluronidase (1 U/ml) [alone or together with RAL (RAL+Hyal)] was added to the cultures. 48 hrs later 1 mCi of [
3H]thymidine
was added to each well. All experiments were done in triplicate and repeated 5 times. The results are presented as the mean incorporated counts per
minute 6 SEM of three wells per group. ***p,0.001(RAL versus none, RAL+4-MU, 4-MU-30+RAL and 4-MU-60+RAL; RAL+4-MU, 4-MU-30+RAL and 4-
MU-60+RAL versus none) (student’s t test). C. RAL induces in vitro mouse keratinocyte proliferation which is inhibited by anti-erbB1 and TIMP-3.
Keratinocytes from SKH1 and DBA/1 mice were cultured in 96-well plates. On day 2 of culture, RAL (2 mM), monoclonal anti-human amphiregulin
neutralizing antibody (100 ng/ml), monoclonal anti-human erbB1 neutralizing antibody (isotype IgG1) (100 ng/ml) or mouse recombinant TIMP-3
(100 ng/ml) was added to the cultures. Mouse IgG1 was used as a control of anti-erbB1. 48 hrs later 1 mCi of [
3H]thymidine was added to each well.
All experiments were done in triplicate and repeated 5 times. The results are presented as the mean incorporated counts per minute 6 SEM of three
wells per group. ***p,0.001(RAL versus none; anti-AR+RAL versus none; anti-erbB1+RAL versus none; TIMP3+RAL versus none; mouse IgG1 versus
RAL) (student’s t test). D. RAL and HAFi show a synergy in vitro which is CD44- and HB-EGF-dependent. Keratinocytes from SKH1, DBA/1 and CD44-/-
mice were cultured in 96-well plates. On day 2 of culture, RAL (2 mM), HAFi (100 mg/ml), human HB-EGF (50 ng/ml) or mouse anti-human HB-EGF
neutralizing antibody (100 ng/ml) was added to the cultures. 48 hrs later 1 mCi of [
3H]thymidine was added to each well. All experiments were done
in triplicate and repeated 5 times. The results are presented as the mean incorporated counts per minute 6 SEM of three wells per group. ***p,0.001
(HAFi, RAL+HAFi and HB-EGF versus none; anti-HB-EGF+HAFi versus HAFi; anti-HB-EGF+RAL+HAFi versus RAL+HAFi); **p,0.01 (RAL versus none; HB-
EGF versus none; anti-HB-EGF+RAL versus RAL; antiHB-EGF+HAFi versus HAFi) (student’s t test).
doi:10.1371/journal.pone.0014372.g001
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and mRNA expression of CD44 in mouse skin
Immunostaining of vehicle-treated back skin of DBA/1 mice
revealed the standard expression of CD44 in basal and suprabasal
keratinocytes (Figure 3A, a). However, topical application of RAL
and HAFi for 3 days significantly increased CD44 expression in
follicular (data not shown) and interfollicular keratinocytes
(Figure 3A, d), as shown by using an antibody recognizing all
CD44 isoforms. The staining intensity for CD44 was stronger in
HAFi alone- and RAL- and HAFi-treated epidermis than the one
treated with RAL alone (Figure 3A, b, c, d). An antibody which
specifically recognizes CD44v3 isoform revealed increased expres-
sion of CD44v3 in suprabasal keratinocytes with the exception of
the basal and granular layer after topical application of RAL and
HAFi (Figure 3B, a, b, c, d). The staining for CD44v3 was stronger
in the upper suprabasal layers in the RAL alone- and RAL- and
HAFi-treated epidermis when compared to the one treated with
HAFi alone (Figure 3B, b, c, d). Although RAL seemed to increase
the expression of CD44 more at the RNA level (Figure 3D), the
protein expression of CD44 was more augmented by HAFi
(Figure 3C). CD44 expression in RAL- and HAFi-treated SKH1
hairlessorDBA/1 mouse back skinwasmore significantly increased
than in RAL alone- or HAFi alone- treated skin of these mice both
at the RNA and protein levels (Figure 3C, D).
RAL and HAFi have a synergistic effect on the epidermal
and dermal HA production in mouse skin
Quantification of epidermal and dermal HA was performed by
an enzyme-linked binding protein assay on the RAL-, HAFi, and
RAL and HAFi-treatedepidermis and dermis of SKH1 hairless(not
shown) and DBA/1 mice. RAL alone seemed to increase more
epidermal HA than HAFi alone (Figure 4A). In contrast, HAFi
alone resulted in more HA in dermis than RAL alone (Figure 4B).
RAL and HAFi combination more significantly increased epider-
mal and dermal HA than with RAL or HAFi alone (Figure 4A, B).
RAL and HAFi have a synergistic effect on the protein
expression of pro-HB-EGF in mouse skin
To address the effect of the combination of topically-applied RAL
and HAFion the expression of CD44v3, pro- and active HB-EGF and
its receptor erbB1 in vivo, we performed a western blot analysis on the
protein extracts of RAL- and HAFi-treated SKH1 hairless mice. RAL
alone-treated epidermis showed a slight increase of CD44v3 (data not
shown), active HB-EGF and erbB1 protein expression when
compared to vehicle-treated epidermis (Figure 5A, a, c). Protein
content of pro-HB-EGF was not increased by RAL (Figure 5A, b).
HAFi alone-treatment resulted in an increase of CD44v3 (data not
shown), pro- and active HB-EGF, and erbB1 protein expression when
compared to vehicle-treated epidermis (Figure 5A, a, b, c). HAFi
i n c r e a s e da c t i v eH B - E G Fm o r et h a nR A L( F i g u r e5 A ,a ) .T h e r ew a s
no difference between the RAL and HAFi in terms of the increase of
erbB1 (Figure 5A, c). There was no difference in erbB3 expression
between RAL- and vehicle-treated epidermis (data not shown). No
expression of erbB2 or erbB4 was detected in mouse skin (data not
shown). RAL did not influence the expression of MMP-7 (data not
shown). RAL and HAFi-treatment showed a synergy only on the
expression of pro-HB-EGF (Figure 5A, b).
RAL and HAFi show synergy in the correction of human
skin atrophy
Topical application of RAL and HAFi to the atrophic forearm
skin of elderly dermatoporosis patients for 1 month not only
corrected the skin atrophy but also caused marked skin hyperplasia.
Thiseffect was more significant than RALalone (data not shown) or
HAFi alone (Figure 5B). Clinically, the wrinkles, hematoma and
pseudoscars seen in atrophic skin decreased and smoothening of the
skin was observed after RAL and HAFi treatment (Figure 5C, a, b).
Histologically, the epidermal hyperplasia observed after RAL and
HAFi treatment was associated with a decrease of elastosis an
increase of collagen in the dermis (Figure 5C, c, d).
Materials and Methods
Topical retinoid preparation
RAL was used at the concentration of 0.05% compounded in an
oil-in-water cream [11].
Preparation of HAFi
HA from rooster comb (IAL) forclinical application was provided
by Transbussan (Geneva, Switzerland). HAFi: Fragmentation
products of HA of medium size (50’000–400’000 Da) was prepared
Figure 2. The effect of RAL and HAFi in vivo.A .The effect of RAL and HAFi in vivo on mouse skin. Histological sections of vehicle- (a), RAL- (b),
HAFi- (c) or RAL- and HAFi- (d) treated DBA/1 and vehicle (e) or RAL- (f) treated CD44-/- mouse dorsal skin. Note the significant epidermal hyperplasia
in DBA/1 but not in CD44-/- mice. B. Epidermal thickness in SKH1, DBA/1 and CD44-/- mouse dorsal skin measured with an ocular micrometer. Ten
measurements were performed per mouse and the average value was calculated. The results are presented as the mean epidermal thickness 6 SEM
of six animals per group. ***p,0.001 versus vehicle (student’s t test). C. Ki67 staining of vehicle- (a), RAL- (b), HAFi- (c) or RAL- and HAFi- (d) treated
DBA/1 and vehicle (e) or RAL- (f) treated CD44-/- mouse dorsal skin.
doi:10.1371/journal.pone.0014372.g002
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were then separated on a Sephacryl S-400 HR 4x80 cm size exclu-
sion gel filtration column (Pharmacia Diagnostics, Uppsala, Sweden).
The column was calibrated using Pullulan standards (Showa-Denko,
Kawasaki, Japan) from 20’000 to 800’000 Da. 100 fractions of 10 ml
each were collected from the column with a Frac. 100 fraction collector
(Pharmacia) at a flow rate of 1 ml/min. The HA concentration of each
sample was determined by a colorimetric dosage according to a BCA
reducing sugar assay and an elution profile for the fragments was
obtained. The fractions corresponding to the 50’000–400’000 Da were
pooled, dialyzed against distilled water and lyophilized. The fragments
were separated by 15% polyacrylamide gel (TBS) electrophoresis and
visualized with an alcian blue and silver staining. HAFi were prepared
in the form of cream in a neutral vehicle.
Treatment of mice
Groups of five adult (.3 month-old) SKH1 hairless, DBA/1
(The Jackson Laboratory, Bar Harbor, ME) or CD44-deficient
(CD44
2/2) mice [14] were used. HAF, RAL or vehicle cream
samples of 0.5 g were applied twice daily for 3 days to the dorsal
skin of SKH1 hairless, DBA/1 or CD44
2/2 mice. The daily
amount of RAL delivered corresponded to 250 mg. Animals were
sacrificed two hours after the last application. All animals were
handled in strict accordance with good animal practice as defined
by the relevant national and/or local animal welfare bodies, and
all animal work was approved by the Ethical Commission on
Animal Experimentation of the University of Geneva and the
Cantonal Veterinary Office of Geneva (ethics approval code
31.1.1035/2368/I).
Treatment of healthy subjects and patients
7 healthy young adults (7 M) between 19 and 32 years (mean
age 25.5 years), 3 patients with advanced age-related dermato-
porosis (2 F; 1 M) between 60 and 88 years (mean age: 76 years)
and 3 patients with dermatoporosis due to prolonged use of oral
corticosteroids (3 F) between 74 and 86 years (mean age: 81 years)
Figure 3. RAL and HAFi have a synergistic effect on the protein and mRNA expression of CD44 in mouse skin. A. Immunostaining of
sections of vehicle- (a), RAL- (b), HAFi- (c) or RAL- and HAFi- (d) treated DBA/1 mouse dorsal skin with anti-CD44 antibodies. Note the hyperplasia and
increase in diffuse CD44 expression in the epidermis in RAL-, HAFi- and RAL- and HAFi-treated mice. B. Immunostaining of sections of vehicle- (a),
RAL- (b), HAFi- (c) or RAL- and HAFi- (d) treated DBA/1 mouse dorsal skin with anti-CD44v3 antibodies. Note the hyperplasia and increase in
suprabasal CD44v3 expression in the epidermis in RAL-, HAFi- and RAL- and HAFi-treated mice. C. Western blot analysis for CD44 (,90 kDa)
performed on the epidermal proteins extracted from the RAL-, HAFi- and RAL- and HAFi-treated skin of SKH1 hairless mice. a-tubulin (50 kDa) has
been used as a loading control. D. Northern blot analysis of CD44 RNA expression in RAL-, HAFi- and RAL- and HAFi-treated skin of DBA/1 mice. Note
the increase of the three CD44 transcripts (5.2, 4.0 and 3.2 kb) in RAL-, HAFi- and RAL- and HAFi-treated skin.
doi:10.1371/journal.pone.0014372.g003
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related dermatoporosis (2 F; 1 M) between 75 and 92 years (mean
age: 84 years) and 3 patients with dermatoporosis due to
prolonged use of oral corticosteroids (2 F; 1 M) between 63 and
77 years (mean age: 71 years) (for RAL and HAFi treatment) were
included in this study after obtaining written informed consent.
Clinical studies were conducted with the authorization and
according to the guidelines of Ethical Commission on Human
Research of the University Hospital of Geneva. 0.05% RAL, 1%
HAFi or vehicle cream samples of 0.5 g were applied twice daily
for 3 months on the posterior side of the right or left arm,
respectively.
Histology
Dorsal skin samples were fixed in 10% phosphate-buffered
formaldehyde, embedded in paraffin, and processed for histolog-
ical analysis. Sections were cut at 5 mm, mounted onto slides, and
stained with hematoxylin-eosin according to standard procedures.
Staining of skin sections for CD44, CD44v3, HABP, Ki-67
Paraffin-embedded sections (5 mm) were mounted onto slides,
de-waxed in xylene, rehydrated in a graded ethanol series and
prepared for immunoperoxidase staining according to standard
procedures. Primary antibodies included: anti-CD44v3 (Bender
MedSytems, Vienna, Austria; 1:100), anti-Ki-67 (Dako, Glostrup,
Denmark; 1:20). After staining with the primary reagent for 1 hr
at room temperature, sections were washed, incubated with
biotinylated affinity-purified secondary antibody or with biotiny-
lated anti-CD44 (PharMingen, San Diego, CA; 2.5 mg/ml) for
30 min at room temperature, washed, and treated with avidin-
biotin-peroxidase for 30 min at room temperature. The sections
were then washed with buffer and incubated in 0.05% DAB (3,39-
diaminobenzidine; Sigma) and 0.03% H2O2 in phosphate buffer
at room temperature. All sections were examined under a Zeiss
axiophot microscope using appropriate filters.
Epidermal and cutaneous thickness measurements
Epidermal thickness of mice was measured by a graded ocular
and multiplied by 10 to correct the scale. Cutaneous thickness
measurements of the healthy subjects and patients were performed
using a skin ultrasound system (Episcan, Longport Inc., Glen Mills,
PA).
Cell proliferation
Epidermal and dermal Ki-67 positive cells were counted in ten
fields per section at 406magnification and the average value was
calculated.
RNA isolation and Northern blotting
Total RNA from the back skin of SKH1 hairless, DBA/1 and
CD44
2/2 mice topically treated with RAL was prepared using a
TRIzol reagent kit (Invitrogen) and digested with RNase-free
DNase 1 (Ambion). Eight micrograms of isolated RNAs were
separated electrophoretically on a 1% agarose gel containing
glyoxal and transferred onto a nitrocellulose membrane. The
membranewasUV-cross-linkedandprobed with[
32P]UTP-labeled
hyaluronate synthase (HAS) cDNA (1610
6 cpm/ml). Hybridiza-
tion with CD44 probe prepared using random primers and CD44
fragment purified from HindIII-EcoRI-digested mCD44H-pBS
plasmid template (Kaya et al, 1997) was performed overnight at
60uC in 50% formamide, 16sodium chloride-sodium citrate, 56
Denhardt’s reagent and 0.2% tRNA. The membrane was washed
twice at 68uC for 30 minutes in 0.16 sodium chloride-sodium
citrate and 0.1% sodiumdodecyl sulfate. Kodak (Rochester, NY)X-
Omat AR film was exposed overnight at 270uC. The integrity of
total RNA was good, and the ratio of 28S and 18S ribosomal RNAs
was ,2:1 in all samples. The hybridization signals were quantitated
by scanning the autoradiograms with a laser densitometer and using
the ImageQuant software.
Western blot analysis
Frozen mouse epidermis or dermis and human biopsy samples
were incubated in extraction buffer containing 20 mM Tris/HCl
(pH 7.5), 100 mM NaCl, 10 mM EDTA, 1% SDS, 10% glycerol
and protease inhibitor cocktail (complete
TM Boehringer, Biberach,
Germany), minced, polytron-homogenized and sonicated on ice.
Cell culture extracts were treated with the same buffer.
Homogenates were spun in a microfuge for 20 min, and the
soluble fraction was extracted and subjected to western blot
analysis with appropriate antibodies.
Figure 4. RAL and HAFi have a synergistic effect on the epidermal and dermal HA production in mouse skin. Epidermal (A) and dermal
(B) HA content of vehicle-, RAL, HAFi- or RAL- and HAFi-treated skin of SKH1 hairless mice quantified by an enzyme-linked binding protein assay. The
results are presented as the mean HA concentration 6 SEM of six animals per group. ***p,0.001 versus vehicle; **p,0.01 versus vehicle; *p,0.05
versus vehicle (student’s t test).
doi:10.1371/journal.pone.0014372.g004
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subjected to electrophoresis, and transblotted onto 0.45 mm pore-
size nitrocellulose membrane. Antibodies used for Western blot
analysis were anti-CD44 standard (Bender MedSytems); anti-
CD44v3 (Bender MedSystems); anti-MMP-7 (G-20) (Santa Cruz
Biotechnology); anti-pro-HB-EGF (M-18) (Santa Cruz Biotech-
nology); anti-HB-EGF neutralizing antibody (R&D Systems,
Minneapolis, MN); and anti-erbB1 and anti-erbB4 (Santa Cruz
Biotechnology).
In vitro keratinocyte proliferation assay
Epidermal keratinocytes were isolated and cultured in 96-well
plates (Becton Dickinson) as described previously [16]. On day 2 of
culture, HAFi (100 mg/ml), RAL (2 mM), RA (2 mM), ROL
(2 mM), ROLP (2 mM), 4-MU (0.6 mM) (Sigma), hyaluronidase
(1 U/ml) (Sigma), RAL+HAFi, RAL+HAFi, RA+HAFi, ROL+
HAFi or ROLP+HAFi, monoclonal anti-human amphiregulin
(AR) neutralizing antibody (100 ng/ml), monoclonal anti-human
erbB1 neutralizing antibody (isotype IgG1) (100 ng/ml), mouse
recombinant TIMP-3 (100 ng/ml) or human HB-EGF (5 ng/ml)
(R&D Systems), TPA (1 ng/ml) (Sigma), human EGF (50 ng/ml)
(Sigma), in the presence or absence of anti-HB-EGF neutralizing
antibody (10 ng/ml) (R&D Systems), was added to the cultures.
Mouse IgG1 was used as a control of anti-erbB1. 48 hrs later
1 mCi of [
3H]thymidine (Amersham, Buckinghamshire, UK) was
added to each well. Isotope incorporation was evaluated 24 hrs
later in a Beckman LS 1801 b counter (Beckman Coulter,
Fullerton, California). All experiments were done in triplicate and
repeated 5 times, and the results were expressed as the mean of
incorporated counts per minute for each condition tested.
Figure 5. The synergistic effect of RAL and HAFi in the protein expression of pro-HB-EGF in mouse skin and in human skin atrophy.
A. Western blot analysis on the protein extracts of vehicle-, RAL-, HAFi- or RAL- and HAFi-treated SKH1 hairless mice for active HB-EGF (,15 kDa) (a),
pro-HB-EGF (,25 kDa) (b) and erbB1 (,170 kDa) (c) and loading control a-tubulin (50 kDa) (d). B. RAL and HAFi show synergy in the correction of
dermatoporosis. Skin thickness in untreated young, untreated atrophic aged, HAFi alone-treated atrophic aged or RAL and HAFi-treated atrophic
aged human skin measured by echography. The results are presented as box-plots with median value (m). p=0.001 (young untreated versus atrophic
aged untreated); p,0.01 (atrophic aged untreated versus atrophic aged treated with HAFi); p,0.001 (atrophic aged untreated versus atrophic aged
treated with RAL and HAFi); p,0.05 (atrophic aged treated with HAFi versus atrophic aged treated with RAL and HAFi) (nonparametric Mann-Whitney
U test). C. Clinical view of atrophic human forearm skin before (a) and 1 month after topical treatment with RAL and HAFi (b). Note the decrease of
wrinkles, hematoma and pseudoscars, and smoothening of the skin after RAL and HAFi treatment. Histological view of atrophic human forearm skin
before (c) and 1 month after topical treatment with RAL and HAFi (d). Note the significant epidermal hyperplasia, decrease of elastosis and increase of
collagen in the dermis after RAL and HAFi treatment.
doi:10.1371/journal.pone.0014372.g005
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Keratinocytes were cultured in six-well culture plates (Falcon,
Becton Dickinson and Co.) as described above. On day 12 of
culture, HAFi (100 mg/ml), a RAL (2 mM) or RAL+HAFi were
added to the cultures. 48 hrs later HA synthesis was determined by
the quantification of HA in the culture supernatants by an
enzyme-linked binding protein assay as described above.
Discussion
In this study we provide evidence that RAL induces an in vitro
and in vivo proliferative response of keratinocytes which is
mediated by a CD44-dependent pathway and that RAL and
HAFi show a synergy in vitro and in vivo with a potential
therapeutic effect in dermatoporosis.
In our previous study we have shown for the first time that
HAFi induce an in vitro keratinocyte proliferation [15]. This
proliferative response was inhibited, like for RAL, by anti-erbB1
blocking antibodies and TIMP-3, an inhibitor of MMPs and
ADAMs, suggesting that the RAL- or HAFi- induced in vitro
proliferative response requires erbB1 and MMPs/ADAMs. In the
present study we show that RAL and HAFi have a synergistic
effect on the in vitro proliferation of keratinocytes. Our previous
and present observations also provide evidence that CD44 and
HB-EGF are required for RAL- or HAF-mediated in vitro
keratinocyte proliferation. The absence of a proliferative response
of CD44
2/2 keratinocytes to HB-EGF is consistent with the
notion that HB-EGF interaction with its receptors requires
presentation by heparan sulfate side chains of CD44v3-containing
isoforms which appear to constitute a major fraction of heparan
sulfate proteoglycans expressed on the surface of normal
keratinocytes [16].
Our observations show that topical application of RAL and
HAFi to normal mouse skin leads to: (1) significant epidermal
hyperplasia accompanied by increased cell proliferation in
epidermis and dermis, (2) increase of CD44 and its CD44v3
isoform, pro- and active HB-EGF, and erbB1 expression, (3)
increase of epidermal and dermal HA.
Significant epidermal hyperplasia and the increased cell
proliferation in epidermis and dermis observed in SKH1 hairless
and DBA/1 mice with topical RAL and HAFi was superior to the
one induced by RAL alone but comparable to the one resulted
from HAFi alone. The comparable result between HAFi alone and
RAL and HAFi combination is most likely due to the saturation of
proliferative capacity of keratinocytes.
Topical RAL and HAF increase the expression of CD44 at the
RNA and protein levels in mouse skin. This increase is more
significant then the one after RAL or HAFi alone, indicating the
synergistic effect of these two molecules on CD44 expression. RAL
and HAF also upregulate the CD44v3 isoform in the epidermis.
However, no synergy was observed in CD44v3 expression. The
synergistic effect of RAL and HAFi on keratinocyte CD44
expression might be due either to a combined effect of RAL and
HAFi on CD44 gene transcription or to a presently unknown
feedback mechanism in order to upregulate the cell surface CD44
for internalization and degradation of increased HA in interker-
atinocyte spaces.
Topical application of RAL and HAF resulted in a significant
increase of pro-HB-EGF and HB-EGF protein levels in mouse
epidermis as well as a slight increase in erbB1 protein expression.
Figure 6. Hypothetical assembly of CD44v3/HB-EGF/erbB1/HAS/Hyal (hyalurosome) complex and the mechanism of RAL and HAFi-
induced keratinocyte proliferation. Schematic representation of the assembly of the putative complex: HAFi mediates CD44v3 and heparan-
sulfate-bound pro-HB-EGF aggregation, resulting in the recruitment and activation of an MMP/ADAM. RAL increases the endogenous HA production
by induction of HAS which will contribute to the aggregation of CD44v3 and pro-HB-EGF and to the activation of MMP/ADAM. Pro-HB-EGF is cleaved
by the MMP/ADAM and the resulting active moiety binds and activates erbB1, generating proliferation signals. Endogenous HA synthesis is controlled
by HA-degrading enzyme hyaluronidase (Hyal).
doi:10.1371/journal.pone.0014372.g006
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not more significant than HAFi alone, a clear synergy was
observed in the induction of pro-HB-EGF expression. The
production of more HB-EGF after RAL and HAFi application
might prolong the proliferative effect on the epidermis by the
generation of more HB-EGF over time which interacts with its
receptor erbB1 which is also upregulated. In our previous study we
showed the association of CD44 with erbB1 in keratinocytes in vitro
and in vivo [15]. This observation is consistent with the notion that
topical HAFi upregulates the molecules shown to form a complex
with CD44 in mouse uterine and mammary epithelia [14], and
that erbB1 blocking antibodies have the same abrogating effect as
the absence of CD44 on in vitro keratinocyte proliferation. It seems
that erbB4 which serves as the receptor for HB-EGF in uterine
and mammary epithelia is replaced by erbB1 in keratinocytes, and
that the same or similar CD44 complex is most likely present on
keratinocytes as well [15].
Topically applied RAL and HAF also show a synergy in the
increase of the epidermal and dermal HA content in mouse skin.
RAL alone increases more HA in epidermis than HAFi alone; in
contrast, HAFi alone results in more dermal HA than RAL alone.
RAL and HAFi application more significantly augments HA in
epidermis and dermis than with RAL or HAFi alone. We recently
showed that the increase in cutaneous HA by RAL is due to the
increased expression of HA-polymerizing enzymes, hyaluronate
synthase (HAS)s 1, 2 and 3 [7]. The synergistic effect on epidermal
and dermal HA increase is most likely due to the upregulation of
HAS1, HAS2 and HAS3 also by HAFi [15]. In our previous study
we demonstrated that topically applied HAFi traverse the skin,
which also contributes the dermal increase of HA [15]. Exogenous
RAL and HAFi as well as the endogenous HA might play an
important role in the activation of CD44 platform which we call
hyalurosome complex which regulates keratinocyte proliferation
and HA metabolism (Figure 6).
Recently we have shown that topical application of HAFi
restores atrophic skin lesions in humans by a CD44-dependent
mechanism [15]. Topical RAL and HAFi application resulted in
skin hyperplasia in dermatoporotic human skin which was more
significant than the one with RAL alone and HAFi alone. This
synergistic effect was observed as early as 1 month after initiation
of treatment and was accompanied by a significant clinical
improvement.
Taken together, our observations suggest that RAL-induced in
vitro and in vivo proliferative response of keratinocytes is mediated
via a CD44-dependent pathway and requires the presence of HB-
EGF, erbB1 and an MMP or ADAM. Therefore CD44-dependent
recruitment and processing of HB-EGF and EGF receptors may
provide a mechanism for cell growth modulation induced by
topical retinoids. Our results also indicate that RAL and HAFi
combination may be used to develop novel therapeutic strategies
for skin atrophy.
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